To test if TG3 is also able to form deamidated peptides that can activate disease-relevant T cells, we stimulated gluten-reactive CeD patient-derived T-cell lines with a whole-gluten digest that had been treated with active TG2 or TG3 (Fig. 1a and Supplementary Fig. 1). The gene discussed is TGM2; the disease is cranioectodermal dysplasia.